Lever A M
Department of Infectious Diseases, Royal Free Hospital, London, U.K.
J Infect. 1988 May;16(3):221-9. doi: 10.1016/s0163-4453(88)97508-1.
Chronic hepatitis B is no longer untreatable. With the advent of powerful antiviral agents such as adenine arabinoside, and, more importantly, with recombinant DNA technology and advanced culture systems able to produce large quantities of interferons, the prospects for treating patients with chronic hepatitis B virus (HBV) infection have changed completely. In the U.K., carriers not infected at birth are currently being treated with an approximately 50% chance of permanently inhibiting viral replication. In some of these, viral markers appear to be completely eliminated.
慢性乙型肝炎已不再无法治疗。随着强力抗病毒药物如阿糖腺苷的出现，更重要的是，随着重组DNA技术以及能够大量生产干扰素的先进培养系统的出现，治疗慢性乙型肝炎病毒（HBV）感染患者的前景已彻底改变。在英国，非出生时即感染的携带者目前正在接受治疗，永久性抑制病毒复制的几率约为50%。其中一些患者的病毒标志物似乎已被完全清除。
